Evolution of therapy decision-making process for advanced non-small cell lung cancer

Vittorio Gebbia, Gianfranco Mancuso, Lucia Lombardi, Evaristo Maiello

Research output: Contribution to journalArticlepeer-review


Advanced non-small cell lung cancer remains a lethal disease with poor prognosis. In the last decades results of systemic chemotherapy have reached a disappointing plateau without significant differences between the most widely employed third-generation regimens. Recent scientific evidence has shed new light on the management of advanced non-small cell lung cancer, especially for the important role of histological definition in therapy-planning process. The results of new biologic agents are also reported as are the promising data on pharmacogenomic-guided treatment.

Original languageEnglish
Pages (from-to)97-102
Number of pages6
Issue numberSUPPL. 1
Publication statusPublished - Feb 2010


  • Biological agents
  • Chemotherapy
  • Histology
  • Lung cancer
  • Pharmacogenomics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Evolution of therapy decision-making process for advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this